04:12 AM EDT, 06/23/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Sunday its investigational type 2 diabetes drug, insulin efsitora alfa, met the primary endpoint in three phase 3 clinical trials.

One of the studies of the once-weekly insulin was performed in adults with type 2 diabetes who used insulin for the first time, the second in patients who previously used daily basal insulin, and the third in people who previously used daily basal insulin and mealtime insulin, the company said.

In the three studies, efsitora doses reduced blood glucose level by 1.31% compared with 1.27% for insulin glargine after 52 weeks, by 0.86% compared with 0.75% for insulin degludec after 26 weeks, and by 1.07% compared with the same reduction level for insulin glargine after 26 weeks, the company said.

Eli Lilly ( LLY ) plans to submit efsitora for the treatment of type 2 diabetes to regulators by the end of the year, it said.